Anti-PIK3CB / PI3 Kinase p110 beta, clone 30P53

Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA. PIK3CB antibody detects phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit beta, also known as PI3 kinase p110 beta. This protein is one of the catalytic isoforms of class I PI3 kinases, which phosphorylate phosphatidylinositol 4,5 bisphosphate to generate phosphatidylinositol 3,4,5 trisphosphate. This lipid second messenger recruits signaling proteins with pleckstrin homology domains to the plasma membrane, initiating downstream signaling cascades that regulate cell growth, proliferation, survival, and metabolism.PIK3CB antibody is widely used in cancer biology, immunology, and metabolic research. PI3 kinase p110 beta is activated downstream of receptor tyrosine kinases, G protein coupled receptors, and integrins, playing a unique role in signaling integration. Dysregulation of PI3 kinase activity contributes to oncogenesis, insulin resistance, and immune dysfunction. By detecting the beta catalytic subunit, researchers can investigate isoform specific functions that differ from those of PI3 kinase alpha, delta, or gamma.The antibody is suitable for western blotting, immunohistochemistry, immunofluorescence, and flow cytometry. In western blot assays, PIK3CB antibody identifies the protein with high specificity, enabling quantitative comparisons across cell types and conditions. Immunohistochemistry localizes expression patterns in tissues, with high levels often detected in tumors. Immunofluorescence studies reveal subcellular localization at the plasma membrane and cytosol, consistent with its role in lipid signaling.PI3 kinase p110 beta has drawn particular attention in oncology. It is frequently upregulated in prostate and breast cancers, and mutations or amplification of PIK3CB drive abnormal cell survival signaling. Targeted inhibition of p110 beta is under active investigation as a therapeutic approach, particularly for tumors resistant to inhibitors of other PI3 kinase isoforms. Monitoring expression with PIK3CB antibody helps define the contribution of this isoform to tumor biology and drug sensitivity.Beyond oncology, PIK3CB antibody is relevant to immunology. PI3 kinase beta regulates platelet activation, neutrophil migration, and T cell signaling. Altered activity contributes to inflammation and autoimmunity, making it an important target for therapeutic modulation. In metabolism research, it plays a role in insulin signaling and glucose homeostasis, with implications for diabetes and metabolic syndrome.PIK3CB antibody offered by NSJ Bioreagents provides a reliable reagent for investigating signaling pathways mediated by PI3 kinase beta. Its specificity ensures accurate detection across experimental methods, supporting studies in cancer, immunity, and metabolism.